Eli Lilly CEO: Our pill supply can 'reach the planet'

Summary

• Eli Lilly has received FDA approval for Foundo (orforglipron), a once-daily oral GLP-1 agonist pill for weight loss, with a future diabetes indication expected.
• The pill's key advantages are accessibility and simplicity: no food effects, can be taken any time of day, and fits easily into existing medication routines.
• Pricing is set at $149-$300+ per month out-of-pocket, with insurance coupons making it $25/month for commercially insured and $50/month for seniors via the upcoming Medicare Part D expansion.
• A core strategic advantage is manufacturing scalability; as a small molecule, it can be produced at a scale sufficient to "reach the planet" and supply global markets without the peptide-based supply constraints of injectables.
• The CEO identifies three major expansion opportunities: 1) ex-US markets (e.g., China, where only 0.5% of the eligible population has tried a GLP-1), 2) new patients previously hesitant about injectables (Novo's oral GLP-1 data shows ~80% of users are new to the category), and 3) maintenance therapy for patients who achieved goals on injectables.
• Persistence (continuation) rates for Zepbound are stated to be higher than the 33% one-year rate cited for Novo's Wegovy, and the oral form is expected to have even better persistence due to simplicity.
• The CEO downplays cannibalization between Lilly's injectable (Zepbound) and oral (Foundo) products, emphasizing a strategy of providing choice within the Lilly portfolio.
• He expresses caution about potential Congressional efforts to codify the MFN (Most Favored Nation) pricing deal into law, fearing it could be distorted and harm industry innovation, but does not regret the original deal.
• Regarding the stock price decline in 2024, he attributes it partially to general market trends and emphasizes focus on driving sales growth, profitability, and pipeline execution rather than short-term valuation.